💊FDA Approval Update | #Hyrnuo (#sevabertinib)
🔸For #HER2-mutant non-small cell lung cancer #NSCLC
⚙️Reversible tyrosine kinase inhibitor targets #EGFR and #HER2 protein
🌟MedChemExpress provides #Sevabertinib for research use.

#NSCLC #TyrosineKinaseInhibitor #TKI #FDA #FDAApproval